|
Published by: Global Markets Direct
Published: Sep. 25, 2012 - 60 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Allergic Conjunctivitis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Allergic Conjunctivitis
- Allergic Conjunctivitis Therapeutics under Development by Companies
- Allergic Conjunctivitis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Allergic Conjunctivitis Therapeutics – Products under Development by Companies
- Allergic Conjunctivitis Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Allergic Conjunctivitis Therapeutics Development
- Bausch & Lomb Incorporated
- Allergan, Inc.
- Bayer HealthCare AG
- Santen Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Limited
- Fovea Pharmaceuticals SA
- LABORATOIRES THEA
- Oxagen Limited
- Morria Biopharmaceuticals Plc
- Allergic Conjunctivitis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Prednisporin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- OC-000459 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ODC-9101 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- mapracorat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- KetoNaph - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AC-150 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Epicutaneous Allergen Patch - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- OPRX - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Olopatadine Hydrochloride + Ketorolac Tromethamine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SUN-1334 H - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- brimonidine tartrate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AC-170 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- T-1210 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- epinastine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allergic Conjunctivitis Therapeutics – Drug Profile Updates
- Allergic Conjunctivitis Therapeutics – Discontinued Products
- Allergic Conjunctivitis Therapeutics - Dormant Products
- Allergic Conjunctivitis – Product Development Milestones
- Featured News & Press Releases
- Mar 22, 2011: ISTA Pharmaceuticals Highlights BEPREVE Clinical Data At 2011 American Academy of Allergy, Asthma and Immunology Annual Meeting
- Nov 26, 2010: Restasis gets Health Canada approval
- Jun 07, 2010: New Efficacy Data Emphasize The Benefit Of Pollinex Quattro Grass
- Jun 07, 2010: CombinatoRx Receives Milestone Payment For Prednisporin Advancement
- May 05, 2010: Foresight Announces Encouraging Data From FST-100 Study In Adenoviral Conjunctivitis Model
- Dec 07, 2009: Stallergenes Announces Positive Three-Year Results Of Phase III Trial With Oralair
- Nov 27, 2009: Stallergenes Receives European Marketing Authorization Approval For Oralair
- Jun 22, 2009: Bausch & Lomb Canada Introduces Lotemax and Alrex
- May 04, 2009: Allergy Therapeutics Announces Submission Of Pollinex Quattro Grass Dossier For European Union ('EU') Regulatory Review
- May 04, 2009: Fovea Reports Positive Results With Prednisporin In Persistent Allergic Conjunctivitis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Allergic Conjunctivitis, H2 2012
- Products under Development for Allergic Conjunctivitis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Bausch & Lomb Incorporated, H2 2012
- Allergan, Inc., H2 2012
- Bayer HealthCare AG, H2 2012
- Santen Pharmaceutical Co., Ltd., H2 2012
- Sun Pharmaceutical Industries Limited, H2 2012
- Fovea Pharmaceuticals SA, H2 2012
- LABORATOIRES THEA, H2 2012
- Oxagen Limited, H2 2012
- Morria Biopharmaceuticals Plc, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Allergic Conjunctivitis Therapeutics – Drug Profile Updates
- Allergic Conjunctivitis Therapeutics – Discontinued Products
- Allergic Conjunctivitis Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Allergic Conjunctivitis, H2 2012
- Products under Development for Allergic Conjunctivitis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractAllergic Conjunctivitis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Allergic Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. Allergic Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Allergic Conjunctivitis.
- A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
